{"product_id":"tgtx-ansoff-analysis","title":"(TGTX) TG Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis TG Therapeutics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you evaluate strategic, R\u0026amp;D, and investment choices; the page includes a real preview\/sample so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI relapsing MS uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRIUMVI is TG Therapeutics’ relapsing MS franchise, so market penetration here means winning more share in the same neurologist and patient pool. In 2024, BRIUMVI net product revenue reached $314.2 million, showing strong uptake in an established market. TG Therapeutics is now pushing deeper use through broader prescriber adoption and earlier treatment starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnti-CD20 differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUblituximab is a glycoengineered anti-CD20 monoclonal antibody, giving TG Therapeutics a clear niche in MS versus older CD20 drugs. In a market led by Roche's Ocrevus, which posted $6.7 billion in 2024 sales, BRIUMVI can target switches and first-line starts by stressing differentiated biology plus twice-yearly dosing after the starter phase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology specialist concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRelapsing MS is a specialist-led market: about 85% of the 1 million Americans living with MS have relapsing forms, and treatment starts with neurologists and MS centers. TG Therapeutics can deepen penetration by focusing BRIUMVI on the same high-prescribing specialists already managing this patient base, so each sales call hits the right decision-maker.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial-stage execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. is in commercial-stage execution, with 1 marketed asset, so market penetration now depends on lifting BRIUMVI demand, share, and repeat use before any broader portfolio push. In 2025, that meant maximizing the current launch base through payer access, physician uptake, and persistence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 marketed product drives growth\u003c\/li\u003e\n\u003cli\u003eLaunch execution sets penetration pace\u003c\/li\u003e\n\u003cli\u003eRevenue scale must come first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrent autoimmune franchise buildout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. is deepening its autoimmune franchise by pushing BRIUMVI in relapsing MS, not by entering a new market. In 2025, that single-product focus kept revenue tied to the same autoimmune platform, so penetration depends on share gains, prescriber expansion, and better patient persistence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCurrent focus: relapsing MS\u003c\/li\u003e\n\u003cli\u003eUses existing autoimmune platform\u003c\/li\u003e\n\u003cli\u003eBuilds share, not new-market reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRIUMVI’s Market Penetration Challenge in Relapsing MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for TG Therapeutics, Inc. means taking more relapsing MS share with BRIUMVI in the same specialist market. BRIUMVI net product revenue was $314.2 million in 2024, while Roche's Ocrevus posted $6.7 billion, so the gap is still wide. The play is deeper neurologist reach, faster starts, and stronger persistence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRIUMVI net product revenue\u003c\/td\u003e\n\u003ctd\u003e$314.2 million, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop rival Ocrevus sales\u003c\/td\u003e\n\u003ctd\u003e$6.7 billion, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget market\u003c\/td\u003e\n\u003ctd\u003eRelapsing MS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes TG Therapeutics, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick TG Therapeutics Ansoff Matrix to clarify growth options and reduce strategy planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, credible sources validating TG Therapeutics growth assumptions to speed due diligence and link each Ansoff growth path to traceable references.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUblituximab in CLL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics is testing ublituximab in chronic lymphocytic leukemia, extending the same anti-CD20 antibody from relapsing MS into a new hematologic cancer market. CLL is large enough to matter: the American Cancer Society projected 23,620 new U.S. cases and 4,460 deaths in 2025. That is classic market development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUblituximab in B-cell NHL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. is testing ublituximab in B-cell non-Hodgkin lymphoma, moving the same antibody into a new oncology segment. NHL still drives about 81,000 new U.S. cases a year and roughly 544,000 global cases, so the addressable market is large. This is market development: new market, same product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology expansion from MS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics has one marketed asset, ublituximab, and that B-cell biology fit makes an MS-to-oncology move logical. Using the same anti-CD20 platform beyond relapsing MS could open B-cell cancer markets such as CLL and NHL without starting from zero. This is market development: one product, one core disease axis, and a wider addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-supported regional reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. can use partner deals with Ildong Pharmaceutical, Rhizen Pharmaceuticals, and LFB Biotechnologies to enter new territories through local development or licensing, which is a low-capital way to grow beyond its direct sales base. In 2025, BRIUMVI net product revenue reached about $311 million, so even modest regional wins could add meaningful upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-led entry reduces upfront launch cost\u003c\/li\u003e\n\u003cli\u003eLicensing fits local regulatory needs\u003c\/li\u003e\n\u003cli\u003e2025 revenue base: about $311 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader alliance network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics’ broader alliance network fits market development by extending current programs through external partners in development and geography. Its ties with Checkpoint Therapeutics, Jiangsu Hengrui Medicine, Novimmune, Ligand, and Jubilant Biosys give it 5 partner links that can speed access to new markets without building every capability in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 named alliance partners\u003c\/li\u003e\n\u003cli\u003eExpand reach across regions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG Therapeutics Expands BRIUMVI Into New Blood-Cancer Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. is using ublituximab in new blood-cancer markets, mainly CLL and B-cell NHL. That is market development: same anti-CD20 platform, new patient pools. 2025 BRIUMVI net product revenue was about $311 million, and U.S. CLL cases were projected at 23,620 in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRIUMVI net revenue\u003c\/td\u003e\n\u003ctd\u003e~$311 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CLL cases\u003c\/td\u003e\n\u003ctd\u003e23,620\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eTG Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, with clear product\/market strategies for TG Therapeutics, Inc. Purchase unlocks the entire in-depth, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCosibelimab advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCosibelimab is a human IgG1 monoclonal antibody that targets PD-L1, adding a new product candidate to TG Therapeutics, Inc. pipeline beyond its 1 current commercial asset. This product development move supports Ansoff matrix diversification by widening the portfolio into a new therapeutic mechanism and market segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG-1701 BTK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG-1701 is an oral, covalently bound Bruton’s tyrosine kinase inhibitor for B-cell diseases. TG Therapeutics says lab screening showed higher BTK selectivity than ibrutinib, which supports a true product-development move in its Ansoff Matrix. It expands the pipeline beyond U.S. XEMBIFY and BRIUMVI, the Company’s core revenue drivers in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG-1801 bispecific antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG-1801 expands TG Therapeutics, Inc. into a new hematologic oncology platform by targeting CD47 and CD19 at the same time. It is a clinical-stage asset, so it adds pipeline depth beyond the Company Name’s approved BRIUMVI franchise, which reported 2025 revenue of $559.5 million. That makes TG-1801 a product development move in Ansoff Matrix terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUmbralisib evaluation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUmbralisib is an oral PI3K-delta and CK1-epsilon inhibitor that TG Therapeutics tested in CLL, marginal zone lymphoma, and follicular lymphoma, so it fit product-level development across B-cell cancers. The program was later withdrawn after safety concerns, so it no longer supports TG Therapeutics' 2025-2026 pipeline growth. TG Therapeutics' 2025 revenue was driven by BRIUMVI, not Umbralisib.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eOral dual-kinase inhibitor\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eStudied in 3 B-cell cancers\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProgram withdrawn after safety issues\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensed preclinical programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. uses licensed preclinical programs in BET, IRAK4, and GITR to widen its pipeline beyond current clinical assets. In Ansoff terms, this is product development: more mechanisms of action for the same immunology and oncology focus. The move adds optionality before launch risk on new assets is fully priced.\u003c\/p\u003e\n\u003cp\u003eThese three programs can feed a longer R\u0026amp;D runway while the company keeps advancing BRIUMVI. With 3 separate preclinical shots on goal, TG Therapeutics, Inc. is not relying on one biology path, which helps reduce pipeline concentration risk and supports future label or platform expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 licensed preclinical programs\u003c\/li\u003e\n\u003cli\u003eBET, IRAK4, and GITR\u003c\/li\u003e\n\u003cli\u003eExtends beyond clinical-stage candidates\u003c\/li\u003e\n\u003cli\u003eAdds new mechanisms of action\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG Therapeutics Expands Beyond BRIUMVI With a Broadening Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. uses product development to widen its pipeline through new mechanisms like cosibelimab, TG-1701, TG-1801, and licensed preclinical BET, IRAK4, and GITR programs. In 2025, BRIUMVI revenue reached $559.5 million, so pipeline expansion supports growth beyond one commercial asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRIUMVI\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003e2025 revenue: $559.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG-1801\u003c\/td\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003eCD47\/CD19 dual target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBET, IRAK4, GITR\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003e3 new mechanisms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePD-L1 checkpoint entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCosibelimab would move TG Therapeutics, Inc. into PD-L1 checkpoint immunotherapy, a clear diversification beyond its B-cell and multiple sclerosis base. It adds a new oncology mechanism and a different patient market, lowering reliance on one therapeutic niche. That said, the move also raises execution risk because oncology commercialization differs sharply from neurology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCD47\/CD19 bispecific entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. moves TG-1801 into the CD47\/CD19 bispecific space, so this is a new product type in a new therapeutic setting. It broadens the pipeline beyond single-target antibodies and reduces reliance on one mechanism, while TG Therapeutics, Inc. still had 1 commercial product in 2025. In Ansoff terms, this is diversification with higher R\u0026amp;D risk but wider future market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBTK class expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTG-1701 adds a BTK inhibitor program, moving TG Therapeutics into a second targeted oncology class beyond its commercial neurology asset, BRIUMVI. That broadens the product mix from a one-drug MS story to a two-platform pipeline. In Ansoff terms, this is clear product diversification and lowers single-asset risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-target preclinical spread\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics, Inc. is diversifying beyond BRIUMVI by pushing BET, IRAK4 and GITR into preclinical work, so the science base now spans epigenetics, innate immunity and immune activation. That is a clear move into new mechanisms and new disease pools, not just more of the same. BRIUMVI has already shown commercial scale, with 2024 net product revenue of $316.6 million, which gives the pipeline room to expand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBET: epigenetics expansion\u003c\/li\u003e\n\u003cli\u003eIRAK4: innate immunity path\u003c\/li\u003e\n\u003cli\u003eGITR: immune activation path\u003c\/li\u003e\n\u003cli\u003eNew targets, new indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExternal innovation model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTG Therapeutics uses an external innovation model with 9 named partners—Checkpoint, Hengrui, Novimmune, Ligand, Jubilant, LFB, GTC, Ildong and Rhizen—so its pipeline is not tied to only one lab or one market. That setup lowers single-product risk and supports a broader, partner-sourced pipeline while BRIUMVI still drives core sales. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e9 collaboration partners\u003c\/li\u003e\n\u003cli\u003eLess dependence on in-house discovery\u003c\/li\u003e\n\u003cli\u003eLower single-product exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTG Therapeutics Expands Beyond BRIUMVI with a Broader Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTG Therapeutics, Inc.’s diversification is clear: it is moving beyond BRIUMVI into oncology and new immune targets. Cosibelimab, TG-1801, TG-1701, and early BET, IRAK4, and GITR work all add new mechanisms and markets. In 2025, BRIUMVI was still the only commercial product, so diversification still matters for risk spread.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosibelimab\u003c\/td\u003e\n\u003ctd\u003eNew PD-L1 class\u003c\/td\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTG-1801\u003c\/td\u003e\n\u003ctd\u003eCD47\/CD19 space\u003c\/td\u003e\n\u003ctd\u003eNew mechanism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e9 named allies\u003c\/td\u003e\n\u003ctd\u003eBroader pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235053904137,"sku":"tgtx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tgtx-ansoff-matrix.webp?v=1785733508","url":"https:\/\/dcfanalyst.com\/products\/tgtx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}